Equities
Health CareMedical Equipment and Services
  • Price (USD)74.34
  • Today's Change4.03 / 5.73%
  • Shares traded5.39m
  • 1 Year change-20.96%
  • Beta1.0970
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy12
Outperform8
Hold6
Sell0
Strong Sell0

Share price forecast in USD

The 24 analysts offering 12 month price targets for DexCom Inc have a median target of 92.50, with a high estimate of 120.00 and a low estimate of 75.00. The median estimate represents a 31.56% increase from the last price of 70.31.
High70.7%120.00
Med31.6%92.50
Low6.7%75.00

Earnings history & estimates in USD

On Oct 24, 2024, DexCom Inc reported 3rd quarter 2024 earnings of 0.45 per share. This result was in line with the consensus of the 20 analysts following the company and under-performed last year's 3rd quarter results by 10.00%.
The next earnings announcement is expected on Feb 06, 2025.
Average growth rate+0.76%
DexCom Inc reported annual 2023 earnings of 1.52 per share on Feb 08, 2024.
Average growth rate+39.96%
More ▼

Revenue history & estimates in USD

DexCom, Inc. had 3rd quarter 2024 revenues of 994.20m. This bettered the 990.71m consensus of the 22 analysts covering the company. This was 34.08% above the prior year's 3rd quarter results.
Average growth rate+0.79%
DexCom, Inc. had revenues for the full year 2023 of 3.62bn. This was 24.49% above the prior year's results.
Average growth rate+25.24%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.